Research
Hormonal
Semaglutide 2.4 mg weekly reduces cardiovascular mortality, myocardial infarction, and stroke in overweight/obese patients without diabetes but with cardiovascular disease.
If you have obesity and existing heart disease, even without diabetes, semaglutide 2.4 mg weekly can significantly reduce your risk of heart attack, stroke, and death. This is a critical benefit beyond weight loss. Discuss this with your doctor to see if you qualify for this treatment.
StrongSupportsVERY_HIGH confidence
The SELECT study demonstrated benefits in reducing cardiovascular mortality, myocardial infarction, and stroke with weekly doses of 2.4 mg semaglutide compared to placebo in overweight or obese patients without diabetes but with underlying cardiovascular disease
Why this rating
Based on the SELECT study, a major randomized controlled trial.
Source
Obesidad, el papel del gastroenterólogo
Valeria Atenea Costa et al. · Revista Colombiana de Gastroenterología · 2024
DOI 10.22516/25007440.1192
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Phentermine-topiramate produces greater weight loss than GLP-1 receptor agonists, but GLP-1 agonists carry a higher risk of adverse events.Good
- Intragastric balloons (IGB) are effective for weight loss but carry risks of dehydration, readmission, and reintervention, with saline-filled balloons outperforming air-filled ones.Good
- Endoscopic Sleeve Gastroplasty (ESG) achieves 16-20% total weight loss at 12 months and improves metabolic markers without worsening GERD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →